Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517157 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL8964136 | 0.91 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL29394365 | 0.91 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL244657 | 0.91 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL421411 | 0.91 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL10072375 | 0.90 | AGTR2 (0.82) | AGTR2AGTR1 | |
| SCHEMBL21881243 | 0.87 | AGTR2 (0.76) | AGTR2AGTR1 | |
| SCHEMBL21881633 | 0.87 | AGTR2 (0.76) | AGTR2AGTR1 | |
| SCHEMBL21881836 | 0.87 | AGTR2 (0.76) | AGTR2AGTR1 | |
| SCHEMBL21881831 | 0.87 | AGTR2 (0.76) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5525614-A | TREATING VASCULAR RESTENOSIS, CNS DISORDERS | WARNER-LAMBERT COMPANY (US) | 1996-06-11 | — | — | US | disclosed |
| US-5489686-A | CARDIOVASCULAR DISORDER, NERVOUS SYSTEM DISORDER, ANTIDIURETIC , PSYCHLOGICAL DISORDER, ANTIDEPRESSANTS | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0641326-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5350757-A | Treatment of vascular restenosis, nervous system disorders and cognition enhancement | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1993023378-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5246943-A | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties | WARNER-LAMBERT COMPANY (US) | 1993-09-21 | — | — | US | disclosed |